Digital technologies loom large on the list—from the growing impact of artificial intelligence to the need for tech-enabled ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Eli Lilly and Company’s LLY shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, ...

When you think back to 2024, what were the most impactful food stories? The Agri-Food Analytics Lab at Dalhousie University ...

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

Medspas are leading the charge in offering GLP-1 treatments, with 60% of medspas in the U.S. now providing these services, compared to 35% of aesthetic physician offices. Average spend per patient ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

In January 2023, the world was abuzz with stories of a revolutionary weight-loss drug – a simple, self-administered injection ...

Sharon Mann has lost nearly 30 pounds since starting on Mounjaro, a GLP-1 medication. Dr. Sanjay Gupta reports.

The GLP-1s include semaglutide (Ozempic, Wegovy) and the combination of GLP-1/GIP drug tirzepatide (Mounjaro, Zepbound).

As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two main factors: human resources and finance. On one side, there's the potential ...